Search

LB-P8

LB-P8 is an investigational live biotherapeutic product consisting of a single bacterial strain (_Leuconostoc citreum_).

Methylthioinosine

An analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.

AMT-080

AMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.

CTX130

CTX130 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD70 antigen.

Levomethadone

Sulfaisodimidine

Sulfaisodimidine also called sulfisomidine is an antibacterial product that has been studied for the treatment of urinary tract infections in the 1950s, however, it is unclear whether this drug has been

Diphenyleneiodonium

An NADPH oxidase 2 (NOX2) inhibitor.[A252987]

LErafAON

Phase I/II trials commenced in March 2001 and were ongoing as of June 2003. … NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation

(1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid

These are compounds containing an acetic acid (or a derivative) linked to the C3 carbon atom of an indole. (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid is known to target interleukin-2. … (1H-indol-3-yl)-(2-mercapto-ethoxyimino)-acetic acid is a solid. This compound belongs to the indole-3-acetic acid derivatives.

Darifenacin

It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments. … This block reduces the urgency to urinate and so it should not be used in people with urinary retention.